Ethics of Phase 1 Oncology Studies: Reexamining the Arguments and Data

JAMA

Volumn 290, Issue 8, 2003, Pages 1075-1082

  Agrawal, Manish ^a,b   Emanuel, Ezekiel J ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GEMCITABINE; INTERLEUKIN 2; IRINOTECAN; TOPOTECAN;

CANCER MORTALITY; CANCER RESEARCH; CANCER SURVIVAL; CANCER THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; COLON CARCINOMA; DAILY LIFE ACTIVITY; DECISION MAKING; DOCTOR PATIENT RELATION; DRUG APPROVAL; ETHICS; FLUID THERAPY; FOOD AND DRUG ADMINISTRATION; HUMAN; INFORMATION PROCESSING; INFORMED CONSENT; KIDNEY CARCINOMA; OVARY CARCINOMA; PANCREAS CARCINOMA; PATIENT ATTITUDE; PATIENT EDUCATION; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; REVIEW; RISK BENEFIT ANALYSIS; SAMPLE SIZE; SEPSIS; TERMINAL DISEASE; TREATMENT OUTCOME; TUMOR VOLUME; VOLUNTEER; ANALYTICAL APPROACH; ARTICLE; BIOMEDICAL AND BEHAVIORAL RESEARCH; EMPIRICAL APPROACH; NEOPLASM; PHASE 1 CLINICAL TRIAL; QUALITY CONTROL; RISK ASSESSMENT; STANDARD; TERMINALLY ILL PATIENT;

ANALYTICAL APPROACH; BIOMEDICAL AND BEHAVIORAL RESEARCH; EMPIRICAL APPROACH;

CLINICAL TRIALS, PHASE I; HUMANS; INFORMED CONSENT; NEOPLASMS; PATIENT EDUCATION; QUALITY CONTROL; RISK ASSESSMENT; TERMINALLY ILL;

EID: 0041920900     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.290.8.1075     Document Type: Review

References (67)

1. Cancer facts & figures 2003. American Cancer Society Web site. Available at: http://www.cancer.org /downloads/STT/CAFF2003 PWSecured.pdf. Accessibility verified July 26, 2003.
2. Arbuck SG. Workshop on phase I study design: Ninth NCI/EORTC New Drug Development Symposium, Amsterdam, March 12, 1996. Ann Oncol. 1996;7:567-573.
3. Ratain MJ, Mick R, Schilsky RL, Siegler M. Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst. 1993;85:1637-1643.
4. Emanuel EJ. A phase I trial on the ethics of phase I trials. J Clin Oncol. 1995;13:1049-1051.
5. Lipsett MB. On the nature and ethics of phase I clinical trials of cancer chemotherapies. JAMA. 1982;248:941-942.
6. Miller M. Phase I cancer trials: a collusion of misunderstanding. Hastings Cent Rep. 2000;30:34-43.
7. Kodish E, Stocking C, Ratain MJ, Kohrman A, Siegler M. Ethical issues in phase I oncology research: a comparison of investigators and institutional review board chairpersons. J Clin Oncol. 1992;10:1810-1816.
8. Penman DT, Holland JC, Bahna GF, et al. Informed consent for investigational chemotherapy: patients' and physicians' perceptions. J Clin Oncol. 1984;2:849-855.
9. Daugherty CK, Banik DM, Janish L, Ratain MJ. Quantitative analysis of ethical issues in phase I trials: a survey interview of 144 advanced cancer patients. IRB. 2000;22:6-14.
10. Joffe S, Cook EF, Cleary PD, Clark JW, Weeks JC. Quality of informed consent in cancer clinical trials: a cross-sectional survey. Lancet. 2001;358:1772-1777.
11. Meropol NJ, Schulman KA, Weinfurt K. Discordant perceptions of patients and their physicians regarding phase I trials. Paper presented at: Proceedings of the American Society of Clinical Oncology; May 18-21, 2002; Orlando, Fla.
12. Moore S. A need to try everything: patient participation in phase I trials. J Adv Nurs. 2001;33:738-747.
13. Rodenhuis S, van den Heuvel WJ, Annyas AA, Koops HS, Sleijfer DT, Mulder NH. Patient motivation and informed consent in a phase I study of an anticancer agent. Eur J Cancer Clin Oncol. 1984;20:457-462.
14. Estey E, Hoth D, Simon R, Marsoni S, Leyland-Jones B, Wittes R. Therapeutic response in phase I trials of antineoplastic agents. Cancer Treat Rep. 1986;70:1105-1115.
15. Decoster G, Stein G, Holdener EE. Responses and toxic deaths in phase I clinical trials. Ann Oncol. 1990;1:175-181.
16. Itoh K, Sasaki Y, Miyata Y, et al. Therapeutic response and potential pitfalls in phase I clinical trials of anticancer agents conducted in Japan. Cancer Chemother Pharmacol. 1994;34:451-454.
17. Von Hoff DD, Turner J. Response rates, duration of response, and dose response effects in phase I studies of antineoplastics. Invest New Drugs. 1991;9:115-122.
18. Annas GJ. The changing landscape of human experimentation: Nuremberg, Helsinki, and beyond. Health Matrix Clevel. 1992;2(2):119-140.
19. Daugherty C, Ratain MJ, Grochowski E, et al. Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol. 1995;13:1062-1072.
20. Smith TL, Lee JJ, Kantarjian HM, Legha SS, Raber MN. Design and results of phase I cancer clinical trials: three-year experience at MD Anderson Cancer Center. J Clin Oncol. 1996;14:287-295.
21. Higby DJ, Wallace HJ Jr, Albert DJ, Holland JF. Diaminodichloroplatinum: a phase I study showing responses in testicular and other tumors. Cancer. 1974;33:1219-1225.
22. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
23. Druker BJ. Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML. Oncogene. 2002;21:8541-8546.
24. Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst. 1997;89:1138-1147.
25. Frei E 3rd. Clinical trials of antitumor agents: experimental design and timeline considerations. Cancer J Sci Am. 1997;3:127-136.
26. Dent SF, Eisenhauer EA. Phase I trial design: are new methodologies being put into practice? Ann Oncol. 1996;7:561-566.
27. Preamble to the Constitution of the World Health Organization as adopted by the International Health Conference, New York, June 19-22, 1946; signed on July 22, 1946, by the representatives of 61 states and entered into force on April 7, 1948. Official Records of the World Health Organization, No. 2:100.
28. Melink TJ, Clark GM, Von Hoff DD. The impact of phase I clinical trials on the quality of life of patients with cancer. Anticancer Drugs. 1992;3:571-576.
29. Berdel WE, Knopf H, Fromm M, et al. Influence of phase I early clinical trials on the quality of life of cancer patients: a pilot study. Anticancer Res. 1988;8:313-321.
30. Quantin X, Riviere A, Daures JP, et al. Phase I-II study of high dose epirubicin plus cisplatin in unresectable non-small-cell lung cancer: searching for the maximal tolerated dose. Am J Clin Oncol. 2000;23:192-196.
31. Cohen L, de Moor C, Parker PA, Amato RJ. Quality of life in patients with metastatic renal cell carcinoma participating in a phase I trial of an autologous tumor-derived vaccine. Urol Oncol. 2002;7:119-124.
32. Francis RJ, Sharma SK, Springer C, et al. A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. Br J Cancer. 2002;87:600-607.
33. Cox K. Enhancing cancer clinical trial management: recommendations from a qualitative study of trial participants' experiences. Psychooncology. 2000;9:314-322.
34. Campbell S, Whyte F. The quality of life of cancer patients participating in phase I clinical trials using SEIQoL-DW. J Adv Nurs. 1999;30:335-343.
35. Sherliker L, Steptoe A. Coping with new treatments for cancer: a feasibility study of daily diary measures. Patient Educ Couns. 2000;40:11-19.
36. Hope-Stone LD, Napier MP, Begent RH, Cushen N, O'Malley D. The importance of measuring quality of life in phase I/II trials of cancer therapy-the effects of antibody targeted therapy: part I. Eur J Cancer Care (Engl). 1997;6:267-272.
37. Agrawal M, Danis M. End-of-Life care for terminally ill participants in clinical research. J Palliat Med. 2002;5:729-737.
38. Hutchison C. Phase I trials in cancer patients: participants' perceptions. Eur J Cancer Care (Engl). 1998;7:15-22.
39. Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical? JAMA. 2000;283:2701-2711.
40. Weijer C. The ethical analysis of risk. J Law Med Ethics. 2000;28:344-361.
41. King NM. Defining and describing benefit appropriately in clinical trials. J Law Med Ethics. 2000;28:332-343.
42. Meslin EM. Protecting human subjects from harm through improved risk judgments, IRB. 1990;12:7-10.
43. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13:688-696.
44. Creemers GJ, Bolis G, Gore M, et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase 11 study. J Clin Oncol. 1996;14:3056-3061.
45. Saltz LB, Cox JV, Blanke C, et al, for the Irinotecan Study Group. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2000;343:905-914
46. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.
47. Fisher B, Dignam J, Tan-Chiu E, et al. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. J Natl Cancer Inst. 2001;93:112-120.
48. Lippman ME, Hayes DF. Adjuvant therapy for all patients with breast cancer? J Natl Cancer Inst. 2001;93:80-82.
49. Van Luijn HE, Musschenga AW, Keus RB, Robinson WM, Aaronson NK. Assessment of the risk/ benefit ratio of phase II cancer clinical trials by institutional review board (IRB) members. Ann Oncol. 2002;13:1307-1313.
50. Epstein AM, Hall JA, Tognetti J, Son LH, Conant L Jr. Using proxies to evaluate quality of life: can they provide valid information about patients' health status and satisfaction with medical care? Med Care. 1989;27(3 suppl):S91-S98.
51. McCusker J, Stoddard AM. Use of a surrogate for the Sickness Impact Profile. Med Care. 1984;22:789-795.
52. Magaziner J, Simonsick EM, Kashner TM, Hebel JR. Patient-proxy response comparability on measures of patient health and functional status. J Clin Epidemiol. 1988;41:1065-1074.
53. Rubenstein LZ, Schairer C, Wieland GD, Kane R. Systematic biases in functional status assessment of elderly adults: effects of different data sources. J Gerontol. 1984;39:686-691.
54. Zweibel NR, Cassel CK. Treatment choices at the end of life: a comparison of decisions by older patients and their physician-selected proxies. Gerontologist. 1989;29:615-621.
55. Slevin ML, Stubbs L, Plant HJ, et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ. 1990;300:1458-1460.
56. Research Involving Persons With Mental Disorders That May Affect Decision-Making Capacity. Washington, DC: National Bioethics Advisory Commission; December 1998.
57. Stolberg S. Teenager's death is shaking up field of human gene therapy experiments. The New York Times. January 27, 2000; sect A:20.
58. Miller M. Phase I cancer trials: a crucible of competing priorities. Int Anesthesiol Clin. 2001;39:13-33.
59. Cheng JD, Hitt J, Koczwara B, et al. Impact of quality of life on patient expectations regarding phase I clinical trials. J Clin Oncol. 2000;18:421-428.
60. Berg JW, Appelbaum PS, Lidz CW, Parker LS. Informed Consent: Legal Theory and Clinical Practice. 2nd ed. New York, NY: Oxford University Press; 2001.
61. Horng S, Emanuel EJ, Wilfond B, Rackoff J, Martz K, Grady C. Descriptions of benefits and risks in consent forms for phase 1 oncology trials. N Engl J Med. 2002;347:2134-2140.
62. Tomamichel M, Sessa C, Herzig S, et al. Informed consent for phase I studies: evaluation of quantity and quality of information provided to patients. Ann Oncol. 1995;6:363-369.
63. Itoh K, Sasaki Y, Fujii H, et al. Patients in phase J trials of anti-cancer agents in Japan: motivation, comprehension and expectations. Br J Cancer. 1997;76:107-113.
64. Yoder LH, O'Rourke TJ, Etnyre A, Spears DT, Brown TD. Expectations and experiences of patients with cancer participating in phase I clinical trials. Oncol Nurs Forum. 1997;24:891-896.
65. Wertheimer A. Coercion. Princeton, NJ: Princeton University Press; 1987.
66. Faden R, Beauchamp T. A History and Theory of Informed Consent. New York, NY: Oxford University Press; 1986.
67. Daugherty CK, Siegler M, Ratain MJ, Zimmer G. Learning from our patients: one participant's impact on clinical trial research and informed consent. Ann Intern Med. 1997;126:892-897.